Janux Therapeutics, Inc.
JANX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001817713
No open-market purchases or sales by Janux Therapeutics, Inc. insiders were filed in the last 90 days; 197 institutions reported holding it in 13F filings for Q2 2026, worth $933.4M in total; no superinvestor holds it.
13F holders, Q2 2021
Institutional positions in Janux Therapeutics, Inc. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 30
- +30 vs. Q1 2021
- Shares held
- 24.7M
- +24.7M vs. Q1 2021
- Total value
- $614.5M
- +$614.5M vs. Q1 2021
- New holders
- 30
- 0 more added
- Sold out
- 0
- 0 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting JANX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 197 | $933.4M |
| Q1 2026 | 190 | $827.8M |
| Q4 2025 | 176 | $860.0M |
| Q3 2025 | 174 | $1.59B |
| Q2 2025 | 174 | $1.51B |
| Q1 2025 | 181 | $1.81B |
| Q4 2024 | 216 | $3.43B |
| Q3 2024 | 160 | $2.07B |
| Q2 2024 | 155 | $1.87B |
| Q1 2024 | 121 | $1.59B |
| Q4 2023 | 64 | $359.5M |
| Q3 2023 | 57 | $354.0M |
| Q2 2023 | 54 | $362.1M |
| Q1 2023 | 48 | $369.5M |
| Q4 2022 | 50 | $381.3M |
| Q3 2022 | 49 | $400.3M |
| Q2 2022 | 44 | $353.0M |
| Q1 2022 | 47 | $407.1M |
| Q4 2021 | 46 | $541.6M |
| Q3 2021 | 45 | $571.2M |
| Q2 2021 | 30 | $614.5M |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Janux Therapeutics, Inc.; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| US Bancorp | 7 | $0 | 0.00% | +7 | New |
| Morgan Stanley | 100 | $2.00K | 0.00% | +100 | New |
| UBS Group AG | 353 | $9.00K | 0.00% | +353 | New |
| JPMorgan Chase & Co | 646 | $16.0K | 0.00% | +646 | New |
| Royal Bank of Canada | 1,300 | $32.0K | 0.00% | +1,300 | New |
| Bank of America Corp | 2,048 | $52.0K | 0.00% | +2,048 | New |
| Wellington Management Group LLP | 9,165 | $229.0K | 0.00% | +9,165 | New |
| Qube Research & Technologies Ltd | 14,309 | $357.0K | 0.00% | +14,309 | New |
| Geode Capital Management, LLC | 22,017 | $549.0K | 0.00% | +22,017 | New |
| ExodusPoint Capital Management, LP | 24,567 | $613.0K | 0.01% | +24,567 | New |
| Vanguard Group Inc | 28,976 | $723.0K | 0.00% | +28,976 | New |
| Pinz Capital Management, LP | 32,100 | $801.0K | 0.24% | +32,100 | New |
| LMR Partners LLP | 57,000 | $1.42M | 0.02% | +57,000 | New |
| Goldman Sachs Group Inc | 69,000 | $1.72M | 0.00% | +69,000 | New |
| Millennium Management LLC | 75,257 | $1.88M | 0.00% | +75,257 | New |
| Citigroup Inc | 86,695 | $2.16M | 0.00% | +86,695 | New |
| BlackRock Inc. | 109,947 | $2.74M | 0.00% | +109,947 | New |
| Woodline Partners LP | 334,260 | $8.34M | 0.16% | +334,260 | New |
| 5AM Venture Management, LLC | 446,266 | $11.1M | 2.80% | +446,266 | New |
| Adage Capital Partners GP, L.L.C. | 450,000 | $11.2M | 0.02% | +450,000 | New |
| Logos Global Management LP | 547,122 | $13.7M | 1.17% | +547,122 | New |
| Samsara BioCapital, LLC | 607,949 | $15.2M | 1.99% | +607,949 | New |
| Deerfield Management Company, L.P. (Series C) | 700,000 | $17.5M | 0.31% | +700,000 | New |
| BVF Inc | 1,176,681 | $29.4M | 1.10% | +1,176,681 | New |
| EcoR1 Capital, LLC | 1,411,975 | $35.2M | 1.32% | +1,411,975 | New |
| FMR LLC | 1,843,564 | $46.0M | 0.00% | +1,843,564 | New |
| Citadel Advisors LLC | 1,886,712 | $46.2M | 0.05% | +1,886,712 | New |
| Janus Henderson Group PLC | 2,668,207 | $64.5M | 0.03% | +2,668,207 | New |
| OrbiMed Advisors LLC | 3,466,386 | $86.5M | 0.88% | +3,466,386 | New |
| Ra Capital Management, L.P. | 8,670,644 | $216.3M | 3.47% | +8,670,644 | New |